ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-GFRAL Monoclonal Antibody NGM120

Also written as “NGM120 Q4W”, “NGM120 Q8W” and “NGM120 30mg”.

Its studies are mostly in Colorectal Neoplasms · Pancreatic Neoplasms · Cachexia, led by NGM Biopharmaceuticals.

Drug pageAnti-GFRAL Monoclonal Antibody NGM120: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Aug 22, 20193 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NGM Biopharmaceuticals31 open or runningphase 2since Aug 22, 2019Dec 8, 2017Apr 2027phase 2 · NCT07033026

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 8, 2017First study: phase 1 study in CachexiaFirst studyNCT03392116 · 92 enrolled · Australia
  2. Aug 22, 2019Phase 2 study in Pancreatic NeoplasmsNCT04068896 · 89 enrolled · United States
  3. Jun 13, 2025Phase 2 study in Colorectal NeoplasmsNCT07033026 · 136 planned · United States, Georgia, South Korea and more

Ahead

  1. Apr 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07033026

TargetBeta

GFRAL →read by rule
“A long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07033026Colorectal Neoplasms · United States, Georgia, South Korea and more2RecruitingApr 2027136
NCT04068896Pancreatic Neoplasms · United States2CompletedSep 21, 202389
NCT03392116Cachexia · Australia1CompletedJan 14, 201992

How it is read

Names in the registry

  • “NGM120 Q4W”, 1 entry
  • “NGM120 Q8W”, 1 entry
  • “NGM120 30mg”, 1 entry
  • “NGM120 100mg”, 1 entry
  • “NGM120 30mg with Gemcitabine and Abraxane”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.